CLAIMS

1. A compound comprising a modified oligonucleotide 14 to 30 linked nucleosides in length having

i) a nucleobase sequence comprising at least 14 contiguous nucleobases of SEQ ID NO: 2879;

ii) a nucleobase sequence comprising a portion of at least 14 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 87,359-90,915; 90,968-97,263; 83,573-87,287; 3,404-44,737; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1,

iii) a nucleobase sequence complementary to intron 12, intron 13, intron 11, intron 1, intron 14, exon 10, or the 3'-UTR of a human DNM2 pre-mRNA or human DNM2 mRNA, or

iv) a nucleobase sequence comprising at least 12, at least 13, at least 14, or at least 15 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 7-3134.

2. The compound of according to claim 1, wherein the modified oligonucleotide has a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 2123, 2189, 2160, 3056, 2453, or 2232.

3. The compound or according to claim 1 or claim 2, wherein the modified oligonucleotide comprises:

a gap segment consisting of 8-12 linked 2'-deoxynucleosides, preferably 10 linked 2'-deoxynucleosides;

a 5' wing segment consisting of 1-7 linked nucleosides, preferably 3 linked nucleosides; and

a 3' wing segment consisting of 1-7 linked nucleosides, preferably 3 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each terminal wing nucleoside comprises a modified sugar.

4. The compound of according to claim 1, wherein the modified oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to any of SEQ ID NOs: 1, 2, 3, or 3135.

5. The compound according to any one of claims 1 to 4, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, preferably a phosphorothioate internucleoside linkage.

6. The compound according to any one of claims 1 to 5, wherein the modified oligonucleotide comprises at least one bicyclic sugar, preferably selected from the group consisting of LNA, ENA, and cEt.

7. The compound according to any one of claims 1 to 6, wherein the modified oligonucleotide comprises at least one 5 -methylcytosine.

8. The compound according to any one of claims 1 to 7, wherein the compound is single-stranded.

9. The compound according to any one of claims 1 to 7, wherein the compound is double-stranded.


10. The compound according to any one of claims 1 to 9, wherein the modified oligonucleotide consists of 16 to 20 linked nucleosides.

11. A compound comprising a modified oligonucleotide according to the following formula: Gks Tks Tks Tds Ads Tds Tds Ads Tds Ads Gds Gds Gds mCks Tks Tk; wherein,

A = an adenine,
mC = a 5-methylcytosine
G = a guanine,
T = a thymine,
k = a cEt sugar moiety,
d = a 2'-deoxyribosyl sugar moiety, and
s = a phosphorothioate internucleoside linkage.

12. The compound according to any one of claims 1 to 11 comprising a conjugate group, preferably wherein the compound consists of the modified oligonucleotide and the conjugate group.


13. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2879), or a salt thereof.

14. The modified oligonucleotide of claim 13, which is the sodium salt or the potassium salt.


15. A modified oligonucleotide, wherein the anion form of the modified oligonucleotide has the following chemical structure:



(SEQ ID NO : 2879).

16. The modified oligonucleotide of claim 15, wherein the modified oligonucleotide is a salt, optionally wherein the cation of the salt is sodium or potassium.

17. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2879).

18. A compound consisting of a pharmaceutically acceptable salt form of any one of the compounds according to any one of claims 1 to 12, preferably wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

19. A chirally enriched population of the compounds according to any one of claims 1 to 12, or of the modified oligonucleotides according to any one of claims 13 to 17, wherein the population is enriched for modified oligonucleotides comprising at least one particular phosphorothioate internucleoside linkage having a particular stereochemical configuration.

20. A pharmaceutical composition comprising the compound according to any one of claims 1 to 12 or 18, the modified oligonucleotide according to any one of claims 13 to 17, or the population according to claim 19 and at least one pharmaceutically acceptable diluent or carrier, optionally wherein the pharmaceutically acceptable diluent is phosphate buffered

saline, and optionally wherein the pharmaceutical composition consists essentially of the modified oligonucleotide(s) and phosphate buffered saline.

21. Use of a compound according to any one of claims 1 to 12 or 18, the modified oligonucleotide according to any one of claims 13 to 17, the population of claim 19 or the pharmaceutical composition of claim 20 in the preparation of a medicament for treating, preventing or ameliorating a diseased associated DNM2 in an individual, optionally wherein the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, Charcot-Marie Tooth disease, X-linked myotubular myopathy, autosomal recessive centronuclear myopathy, or autosomal dominant centronuclear myopathy, and optionally wherein the disease is associated with a mutation in at least one gene selected from among MTM1, BIN1, and DNM2.

22. Use of a compound according to any one of claims 1 to 12 or 18, the modified oligonucleotide according to any one of claims 13 to 17, the population of claim 19 or the pharmaceutical composition of claim 20 in the preparation of a medicament for reducing DNM2 RNA in a cell.